Bayer AG has entered a $1.3 billion global collaboration with Kumquat Biosciences to develop and commercialize a KRAS G12D inhibitor, focusing on pancreatic, colorectal, and lung cancers. The KRAS G12D mutation, prevalent in aggressive cancers, historically lacked effective treatments. Kumquat will conduct the initial phase Ia trial following FDA IND clearance, after which Bayer will assume development and commercialization responsibilities. This partnership adds to Bayer's precision oncology portfolio and bolsters efforts against a significant oncogenic driver implicated in a substantial fraction of human cancers.